FOx BIOSYSTEMS launches the White FOx, its new generation biosensor with fiber-optic surface plasmon resonance
FOx BIOSYSTEMS today announced the launch of their novel biosensor, the White FOx. Through recent collaborations with scientists and engineers, on a range of EU projects, FOx BIOSYSTEMS have created a robust, low maintenance, easy-to-use instrument capable of delivering precise results in real time.
Complix signs Global Drug Discovery and Development Agreement with I-Mab to develop cell penetrating Alphabodies against two intracellular Immuno-oncology targets
Complix, a biopharmaceutical company developing a pipeline of transformative Alphabody therapeutics announces that it has signed a significant drug discovery deal with I-Mab (Nasdaq: IMAB), an innovation-driven clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel and highly differentiated biologics in the immuno-oncology therapeutic area.
Archer Research proud member of BeCRO
Resident Archer Research is now a member of BeCRO (Belgian Association of Contract Research Organisations). Archer Research is in fact the first member fully specialized in the Medical Device Industry to join this association.
Countering the disposable culture in the healthcare industry
REPOMED wants to put a stop to the disposable culture in the healthcare industry. "Today, the majority of medical waste goes into the incinerator.”
DoseVue obtains CE Mark for its first in-vivo dosimetry product for radiation therapy
Diepenbeek, Belgium – January 28, 2021 – DoseVue NV, a privately held medical device company developing in-vivo dosimetry solutions for radiation therapy, today announces the CE marking of its first product: the DoseWire™ Series 200.
FOx Biosystems appoints new CEO
FOx Biosystems’ Board of Directors announces the appointment of Thomas van Elzakker as Chief Executive Officer per 1 September 2020. Van Elzakker takes over from company co-founder Filip Delport who takes up the position of Chief Technology Officer to further develop the proprietary FOx FO-SPR technology.